Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:EVOK NASDAQ:ITRM NASDAQ:JAGX NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$1.56-4.3%$1.09$0.65▼$26.25$17.33M1.23781,301 shs532,553 shsEVOKEvoke Pharma$6.01-1.6%$3.27$1.94▼$12.32$9.12M-0.04698,765 shs629,214 shsITRMIterum Therapeutics$1.13+4.6%$0.99$0.81▼$3.02$43.20M2.791.08 million shs1.90 million shsJAGXJaguar Animal Health$2.70+2.7%$4.48$2.43▼$110.75$2.68M0.5655,413 shs177,317 shsMBRXMoleculin Biotech$0.55+3.0%$0.70$0.25▼$4.71$7.54M1.382.47 million shs2.85 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-4.29%-28.93%+54.46%+65.96%-91.63%EVOKEvoke Pharma-1.64%+122.18%+100.33%+173.18%-12.90%ITRMIterum Therapeutics+4.63%+18.82%+8.65%+1.80%-23.13%JAGXJaguar Animal Health+2.66%+5.26%-29.13%-51.53%-97.33%MBRXMoleculin Biotech+3.01%+57.17%-20.22%-31.22%-83.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTXRCitius Pharmaceuticals3.1742 of 5 stars3.44.00.00.02.80.81.3EVOKEvoke Pharma0.8797 of 5 stars0.05.00.00.03.20.00.0ITRMIterum Therapeutics1.7525 of 5 stars3.53.00.00.02.20.00.0JAGXJaguar Animal Health2.7266 of 5 stars3.55.00.00.02.20.00.6MBRXMoleculin Biotech3.2353 of 5 stars3.52.00.00.04.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.80Moderate Buy$53.003,297.44% UpsideEVOKEvoke Pharma 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.00696.46% UpsideJAGXJaguar Animal Health 3.00Buy$60.002,122.22% UpsideMBRXMoleculin Biotech 3.00Buy$4.00627.14% UpsideCurrent Analyst Ratings BreakdownLatest EVOK, ITRM, JAGX, MBRX, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.006/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.005/23/2025CTXRCitius PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold5/23/2025CTXRCitius PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.005/15/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/8/2025ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AEVOKEvoke Pharma$10.25M0.87N/AN/A$4.74 per share1.27ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AJAGXJaguar Animal Health$11.69M0.24N/AN/A$12.29 per share0.22MBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$39.14MN/A0.001.25N/AN/A-58.63%-37.67%8/11/2025 (Estimated)EVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.99N/A∞N/AN/AN/A-71.37%8/13/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)Latest EVOK, ITRM, JAGX, MBRX, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million5/14/2025Q2 2025CTXRCitius Pharmaceuticals-$1.08-$1.27-$0.19-$1.27N/AN/A5/13/2025Q1 2025ITRMIterum Therapeutics-$0.14-$0.14N/A-$0.14N/AN/A5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.370.06EVOKEvoke PharmaN/A1.551.50ITRMIterum TherapeuticsN/A3.723.58JAGXJaguar Animal Health22.201.080.70MBRXMoleculin BiotechN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%EVOKEvoke PharmaN/AITRMIterum Therapeutics9.21%JAGXJaguar Animal Health12.04%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals10.70%EVOKEvoke Pharma2.29%ITRMIterum Therapeutics9.20%JAGXJaguar Animal Health0.38%MBRXMoleculin Biotech1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2010.63 million9.50 millionOptionableEVOKEvoke Pharma41.49 million1.46 millionNot OptionableITRMIterum Therapeutics1040.00 million36.32 millionNot OptionableJAGXJaguar Animal Health501.02 million1.01 millionNo DataMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableEVOK, ITRM, JAGX, MBRX, and CTXR HeadlinesRecent News About These CompaniesMoleculin Biotech Enters New Stock Offering AgreementJuly 11 at 6:27 PM | tipranks.comMoleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 ... - NasdaqJuly 11 at 9:00 AM | nasdaq.comMoleculin Biotech, Inc.: Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future PlansJuly 9 at 7:06 PM | finanznachrichten.deMoleculin Biotech receives approval for pivotal Phase 2B/3 study of AnnamycinJuly 9 at 7:06 PM | msn.comMoleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future PlansJuly 9 at 8:35 AM | globenewswire.comSeveral Insiders Invested In Moleculin Biotech Flagging Positive NewsJuly 4, 2025 | finance.yahoo.comMoleculin Biotech Faces Nasdaq Delisting WarningJune 27, 2025 | tipranks.comMBRX Moleculin Biotech, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comMoleculin Biotech, Inc. (NASDAQ:MBRX) CFO Acquires $99,999.90 in StockJune 24, 2025 | insidertrades.comMoleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AMLJune 20, 2025 | nasdaq.comMoleculin Biotech prices $5.9M public offering; shares down about 47%June 20, 2025 | msn.comMoleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E WarrantsJune 20, 2025 | quiverquant.comQMoleculin Announces $5.9 Million Public OfferingJune 20, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical StudyJune 18, 2025 | quiverquant.comQMoleculin Participates in Virtual Investor “What This Means” SegmentJune 18, 2025 | globenewswire.comMoleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | globenewswire.comMoleculin Biotech announces ‘What This Means’ virtual investor segmentJune 12, 2025 | finance.yahoo.comMoleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung MetastasesJune 11, 2025 | quiverquant.comQMoleculin Participates in Virtual Investor “What This Means” SegmentJune 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVOK, ITRM, JAGX, MBRX, and CTXR Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$1.56 -0.07 (-4.29%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.60 +0.04 (+2.88%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Evoke Pharma NASDAQ:EVOK$6.01 -0.10 (-1.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.07 +0.06 (+1.00%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Iterum Therapeutics NASDAQ:ITRM$1.13 +0.05 (+4.63%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.20 +0.07 (+5.75%) As of 07/11/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Jaguar Animal Health NASDAQ:JAGX$2.70 +0.07 (+2.66%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.70 0.00 (0.00%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Moleculin Biotech NASDAQ:MBRX$0.55 +0.02 (+3.01%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.52 -0.03 (-5.65%) As of 07/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
